Proteomics: improving biomarker translation to modern medicine?

Biomarkers are defined as 'measurable characteristics that reflect physiological, pharmacological, or disease processes' according to the European Medicines Agency [1]. The ideal platforms for biomarker discovery include genomic, transcriptomic, proteomic, metabonomic and imaging analyses....

Full description

Saved in:
Bibliographic Details
Published in:Genome medicine 2013-02, Vol.5 (2), p.17-17
Main Authors: Guest, Paul C, Gottschalk, Michael G, Bahn, Sabine
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Biomarkers are defined as 'measurable characteristics that reflect physiological, pharmacological, or disease processes' according to the European Medicines Agency [1]. The ideal platforms for biomarker discovery include genomic, transcriptomic, proteomic, metabonomic and imaging analyses. However, most biomarkers used in clinical studies are based on proteomic applications as the majority of current drug targets are proteins, such as G protein-coupled receptors, ion channels, enzymes and components of hormone signaling pathways [2]. Furthermore, linking the results of biomarker studies using protein-protein interaction approaches can assist in systems biology approaches and could lead to hypothesis generation and identification of new drug targets [3].
ISSN:1756-994X
1756-994X
DOI:10.1186/gm421